23.79k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
|Watchlist||Change today||1-month return||1-year return||Total return|
|The fight against COVID19||+0.37%||-||-||-|
|Symbol||Company name||Last price||Change||% change||Market time||Volume||Avg vol (3-month)||Market cap|
|JNJ||Johnson & Johnson||154.42||-0.98||-0.63%||4:00 pm GMT-5||4.73M||6.76M||371.73B|
|ABBV||AbbVie Inc.||149.28||+1.31||+0.89%||4:00 pm GMT-5||5.58M||4.95M||263.56B|
|PFE||Pfizer Inc.||28.78||+0.15||+0.52%||4:00 pm GMT-5||27.71M||31.41M||162.50B|
|SNY||Sanofi||46.32||+0.26||+0.56%||4:00 pm GMT-5||1.33M||2.07M||116.16B|
|GILD||Gilead Sciences, Inc.||79.02||+0.97||+1.24%||4:00 pm GMT-5||6.20M||5.81M||98.46B|
|REGN||Regeneron Pharmaceuticals, Inc.||840.14||-9.04||-1.06%||4:00 pm GMT-5||359.16k||454.25k||91.53B|
|GSK||GSK plc||35.94||-0.06||-0.17%||4:00 pm GMT-5||1.51M||3.53M||74.02B|
|TAK||Takeda Pharmaceutical Company Limited||14.06||-0.02||-0.14%||4:00 pm GMT-5||838.17k||1.85M||44.12B|
|MRNA||Moderna, Inc.||80.32||+0.37||+0.46%||4:00 pm GMT-5||2.75M||4.11M||30.62B|
|BNTX||BioNTech SE||103.43||+1.50||+1.48%||4:00 pm GMT-5||452.62k||656.24k||24.80B|
|VIR||Vir Biotechnology, Inc.||9.62||+0.03||+0.31%||4:00 pm GMT-5||893.26k||1.42M||1.29B|
|NVAX||Novavax, Inc.||5.57||+0.04||+0.72%||4:00 pm GMT-5||4.99M||7.75M||661.66M|
|INO||Inovio Pharmaceuticals, Inc.||0.38||+0.00||+0.53%||4:00 pm GMT-5||1.64M||3.42M||103.73M|
I have always stated that stocks should not be bought just because they trade at a 52-week low. A new 52-week low does not make a particular stock cheap. In today's video I will look at three dividend stocks trading at their 52-week lows and examine their metrics to determine if the stock is cheap or not.
Readers hoping to buy Gilead Sciences, Inc. ( NASDAQ:GILD ) for its dividend will need to make their move shortly, as...
Shares of Pfizer (NYSE: PFE) have been in an endless tailspin this year -- now down more than 40%. Revenue from its COVID-19 products is down big, and investors are concerned about looming patent cliffs for the business in the years ahead. Let's look at what happened -- and Pfizer's prospects for overcoming this latest challenge.